

New possibilities in the treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)

Shutov E.V

Botkin Clinical City Hospital, Russia.

Abstract

Despite the understanding of the problem of treatment CKD-MBD, success in the treatment of this pathology is very modest. This was primarily due to the absent of effective drugs to achieve target biochemical parameters. Recently, new phosphate binders containing iron and calcimimetics have become available for treatment of CKD-MBD. The aim of the study was to assess the effect of new drugs on CKD-MBD targets, including FGF-23, Klotho, PTH, P, Ca and others. We got a good effect from the use of a combination of calcimimetics and phosphate binders containing iron. Only an assessment of the changes in all disease markers under the influence of new drugs gave us the opportunity to improve approaches to treating CKD-MBD.

Conclusions:

Based on our own research results, we can conclude that in the treatment of CKD -MBD we must use new highly effective drugs to achieve the target parameters, including FGF 23 and Klotho.

Biography:

Prof. Shutov E.V. is working many years on the problem of treating patients with CKD. He heads the largest nephrology center in Russia, where there are excellent results in clinical outcomes (dialysis patients mortality 6-7% per year). He uses his own algorithms for treating complications in these patients (anemia, CKD -MBD, infections, hydration, and cardiovascular disease).

Publication of speakers:

1. Shutov E.V:Marinella Ruospo, Suetonia C Palmer, Patrizia Natale, Jonathan C Craig, Mariacristina Vecchio, Grahame J Elder, and Giovanni FM Strippoli .Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD) Cochrane Database Syst Rev. 2018 Aug; 2018(8)
2. Shutov E.V: Jordi Bover, Pablo Ureña,‡§ César Ruiz-García,*† Iara daSilva,*† Patricia Lescano,*† Jacqueline Patients With Secondary Hyperparathyroidism . Clin J Am Soc Nephrol. 2016 Jan 7; 11(1): 161–174.del Carpio,*† José Ballarín,*† and Mario Cozzolino Clinical and Practical Use of Calcimimetics in Dialysis Shutov E.V: Keith E Eidman1 and James B Wetmore 1, Managing hyperparathyroidism in hemodialysis: role of etelcalcetide Int J Nephrol Renovasc Dis. 2018; 11: 69–80.

Citation: Shutov E.V, New possibilities in the treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD), Webinar on Nephrologists, February 28th , 2021